Loading...

Aging Global Demographics And Pipelines Will Expand Rare Therapies

Published
15 Apr 25
Updated
07 May 25
AnalystHighTarget's Fair Value
US$122.00
55.2% undervalued intrinsic discount
10 Sep
US$54.70
Loading
1Y
-20.4%
7D
1.0%

Author's Valuation

US$12255.2% undervalued intrinsic discount

AnalystHighTarget Fair Value

Shared on07 May 25
Fair value Decreased 4.61%

Shared on30 Apr 25
Fair value Increased 1.23%

AnalystHighTarget made no meaningful changes to valuation assumptions.

Shared on23 Apr 25
Fair value Increased 3.55%

AnalystHighTarget has increased future PE multiple from 20.1x to 22.7x.